US Patent

US8883805 — Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines

Formulation · Assigned to Boehringer Ingelheim International GmbH · Expires 2025-11-26 · 0y expired

Vulnerability score 28/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.

USPTO Abstract

The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.

Drugs covered by this patent

Patent Metadata

Patent number
US8883805
Jurisdiction
US
Classification
Formulation
Expires
2025-11-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.